Galectin Therapeutics Inc. (GALT)

[JERZYATP1]

During this month (Jan, 7 and Jan.21, 2016) Dr. Traber has posted two entries on Galectin's blog CEO Perspectives.Those readers open to the possibility Traber is a valuable asset to the Company will find (as I do) what he writes is excellent. Those who feel his performance has rendered the Company a "mess" (adjective actually used), will suggest it's ghost-written and self-serving.
I certainly challenge the "mess" descriptor, for no details are offered. One can only construe that the current low share valuation
is sufficient to gauge a "mess". But this is a clinical-stage company, speculative in nature, requiring some nerve and patience.
In that context it's got odds against it and not much to drive elevation, Time will incur net erosion. And short-sellers are always
wondering if there's room for yet more erosion. Fact is: The Company
is clinically doing its job, is in good standing with the FDA (Fast
Track, and acceptance of drug manufacture), has very high medical aims (and on more than one front (fibrotic- and cancer-diseases)}, managed by well-qualified MDs (Traber and Rubin) and capitally
enabled and guided by a serious financier (Czirr) who himself identifies with the medical aims.
The blog is available via the company website.